▼ Summary
– The WHO condemned a US-funded hepatitis B vaccine trial in Guinea-Bissau as unethical for withholding a safe, established vaccine from some newborns.
– The trial, funded by the CDC under Secretary Robert F. Kennedy Jr., awarded $1.6 million to controversial Danish researchers led by Christine Stabell Benn and Peter Aaby.
– The trial planned to randomize 14,000 newborns to receive the vaccine at birth or six weeks to study alleged safety differences, despite the country’s plan to adopt a birth dose.
– The CDC’s funding followed its advisors, selected by Kennedy, abandoning the universal recommendation for a hepatitis B vaccine birth dose, a move criticized by health experts.
– Guinea-Bissau currently administers the first dose at six weeks due to resource constraints but has already decided to recommend a birth dose starting in 2028.
A major international health body has formally denounced a US-funded medical study, declaring its design fundamentally unethical. The controversy centers on a planned vaccine trial in Guinea-Bissau that would deliberately withhold a proven, safe, and potentially life-saving hepatitis B vaccine from certain newborn participants. This approach, experts argue, violates core principles of medical ethics by denying a known protective intervention to vulnerable infants for the purpose of research.
The World Health Organization issued a sharp critique, stating the trial’s design conflicts with established ethical and scientific standards. Their assessment followed a detailed review of publicly available information, which led to a list of specific concerns about the study’s potential harm and methodological shortcomings. The trial has faced intense scrutiny from the global public health community since details of its US government funding emerged late last year.
Funding for the project originates from the US Centers for Disease Control and Prevention, which awarded $1.6 million to a Danish research team. The grant was issued as a non-competitive, unsolicited award. The research is led by Christine Stabell Benn and Peter Aaby of the Bandim Health Project, affiliated with the University of Southern Denmark. This group has a history of generating controversy through their studies, which often focus on purported vaccine safety issues. Their work has been cited by Health Secretary Robert F. Kennedy Jr., who has moved to reduce global vaccine funding.
The CDC’s decision to finance this particular trial followed another contentious move by the agency. Advisors selected by Kennedy recently opted to discard a longstanding universal recommendation for administering the hepatitis B vaccine at birth. That policy reversal was met with alarm by numerous medical professionals who view the birth dose as a critical public health tool.
In the planned Guinea-Bissau study, researchers aimed to enroll 14,000 newborns. These infants would be randomly assigned to receive their first hepatitis B vaccine either immediately after birth or at the standard six-week mark. The study would then compare outcomes related to alleged safety concerns between the two groups. Notably, Guinea-Bissau currently administers the first dose at six weeks but has already committed to adopting a birth-dose policy by 2028. The delay in implementation is solely due to current resource limitations, not questions about the vaccine’s safety or efficacy at birth.
(Source: Ars Technica)
